Health Research, Inc. Patent applications |
Patent application number | Title | Published |
20160067492 | SYSTEM AND RELATED METHOD TO RESTORE AND/OR IMPROVE NERVOUS SYSTEM FUNCTIONS BY MODIFYING SPECIFIC NERVOUS SYSTEM PATHWAYS - The present invention provides methods, devices, and systems for restoring or improving nervous system function of a subject. Provided is a method involving: (i) providing an operant conditioning protocol effective to produce targeted neural plasticity (TNP) in a primary targeted central nervous system (CNS) pathway of a subject; and (ii) administering the operant conditioning protocol to the subject to elicit TNP in the primary targeted CNS pathway and to elicit generalized neural plasticity (GNP) in one or more other CNS pathway. The elicitation of the GNP in the one or more other CNS pathway serves to restore or improve a nervous system function of the subject. Provided is a device comprising a nerve stimulation-electromyographic recording component and a controller for operating the nerve stimulation-electromyographic recording component in accordance with an operant conditioning protocol. | 03-10-2016 |
20160046668 | TARGETING PEPTIDES AND USES THEREOF - Provided are peptides, fusion proteins which include the peptide sequences, compositions comprising such peptides and fusion proteins, and methods for making and using the compositions. The peptides are characterized as being able to selectively bind to components of the endothelial compartment that are exposed during the period between 1 and 7 days after androgen deprivation. | 02-18-2016 |
20160024083 | COMPOUNDS AND METHODS FOR TREATING CANCERS - Provided are carbazole and carbazole-like compounds (e.g., pyridoindole and pyrrolodipyridine) compounds, that can be used to selectively kill cancer cells, specifically androgen-receptor expressing prostate cancer cells. Also provided is a method of treating AR-positive prostate cancer in a subject diagnosed with or suspected of having AR positive or negative cancer, comprising administering an effective amount of a carbazole and carbazole-like compound to said subject. | 01-28-2016 |
20150025410 | METHOD AND DEVICE TO RESTORE AND/OR IMPROVE NERVOUS SYSTEM FUNCTIONS BY MODIFYING SPECIFIC NERVOUS SYSTEM PATHWAYS - The present invention provides methods, devices, and systems for restoring or improving nervous system function of a subject. Provided is a method involving: (i) providing an operant conditioning protocol effective to produce targeted neural plasticity (TNP) in a primary targeted central nervous system (CNS) pathway of a subject; and (ii) administering the operant conditioning protocol to the subject to elicit TNP in the primary targeted CNS pathway and to elicit generalized neural plasticity (GNP) in one or more other CNS pathway. The elicitation of the GNP in the one or more other CNS pathway serves to restore or improve a nervous system function of the subject. Provided is a device comprising a nerve stimulation-electromyographic recording component and a controller for operating the nerve stimulation-electromyographic recording component in accordance with an operant conditioning protocol. | 01-22-2015 |
20140309170 | ANTI-ANGIOGENIC PEPTIDES AND USES THEREOF - Provided are peptide sequences derived from prostate serum antigen (PSA). The peptides are provided in cyclic and linear form. Methods for using the peptides for inhibition of angiogenesis, such as angiogenesis in a tumor, are provided. | 10-16-2014 |
20140249199 | TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO - The disclosure relates to TAK1 inhibitors, compositions, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula (I), pharmaceutical compositions having a compound of formula (I), and methods of treating or preventing cancer by administering an effective amount of a pharmaceutical composition having a compound of formula (I) to a subject in need thereof. | 09-04-2014 |
20140242058 | ST6GAL I MEDIATED MODULATION OF HEMATOPOIESIS - Provided are methods for reducing haematocytes in an individual. The method involve administering to an individual a composition that contains recombinant a2,6-sialyltransferase (ST6Gal I). The method is suitable for prophylaxis and therapy of a condition that is positively correlated with undesirable hematopoiesis. Such conditions include autoimmune diseases, transplantation rejection, blood cancers and allergic reactions and inflammations. The invention also provides a pharmaceutical preparation that contains recombinant ST6Gal I and which is suitable for administration to an individual to reduce haematocytes in the individual, and a pharmaceutically acceptable carrier. | 08-28-2014 |
20140081015 | METALLATION ENHANCEMENTS IN TUMOR-IMAGING AND PDT THERAPY - A compound in the form of a metallized tetrapyrollic photosensitizer linked to a fluorescent dye where the photosensitizer (PS), is linked by a structure that does not have detrimental radiation emittance or absorbing characteristics, to a fluorophore, usually a cyanine dye (CD). The photosensitizer in accordance the invention is a metallized analog of porphyrins, chlorins, purpurinimides, bacterio pupurinimides, phthalocyanines, expanded porphyrins, benzoporphyrin derivatives and purpurins. The fluorophore is usually a cyanine dye with variable substituents. And, A method for determining effectiveness of PDT by comparing proportion of STAT-3 monomer with crosslinked STAT-3 dimer after PDT where the relative proportion of STAT-3 monomer to crosslinked STAT-3 directly correlates to efficacy of the PDT. | 03-20-2014 |
20140080147 | NOVEL CD3 EPSILON IMMUNOGENS AND ANTIBODIES - The present invention relates to novel CD3 epsilon peptides, antibodies against the novel CD3 epsilon peptides. The invention also relates to methods of identifying an immunodeficiency (such as severe combined immunodeficiency (SCID) or a T cell immunodeficiency) in a patient, which may involve antibodies against CD3 epsilon peptides. | 03-20-2014 |
20140079681 | PRODRUG ANTI-CANCER THERAPY - Compositions and methods for inhibiting the growth of cancer cells are provided. The cancer cells, the growth of which is inhibited, have constitutively active Abl tyrosine kinase activity due to a t(9;22)(q34;q11) translocation which results in expression of a chimeric Bcr-Abl protein which has constitutively active Abl tyrosine kinase activity that is believed to play an important role in leukemogenesis. The compositions include a modified protein kinase C (PKC) which has an Abl tyrosine kinase target motif. The methods involve administering the modified PCK to an individual to inhibit the growth of cancer cells that have Abl tyrosine kinase activity. | 03-20-2014 |
20140066470 | NOVEL FORMULATIONS OF WATER-INSOLUBLE CHEMICAL COMPOUNDS AND METHODS OF USING A FORMULATION OF COMPOUND FL118 FOR CANCER THERAPY - Provided are compositions, methods of making the compositions, and methods of using the compositions. The compositions can be provided as pharmaceutical preparations for use in disease treatment, such as cancer therapy. The compositions include novel pharmaceutical preparations which contain effective concentrations of a chemical compound. One compound used is 10H-1,3-Dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-8,11(7H,12H)-dione, 7-ethyl-7-hydroxy-, (S)-. The invention also provides methodologies for preparing pharmaceutical preparations for use in intravenous and oral pharmaceutical preparations that contain drug compounds that are difficult to dissolve in water. | 03-06-2014 |
20140044724 | ANTI-ENDOGLIN ANTIBODIES AND KNOCKIN MICE EXPRESSING NOVEL HUMAN/MOUSE CHIMERIC ENDOGLIN - Provided are compositions and methods that relate to prophylaxis and therapy of angiogenesis associated disease and includes novel knockin mice which express novel human/mouse chimeric endoglin, vectors for use in making such mice, and murine embryonic stem cells comprising the novel human/mouse transgene. Also provided are anti-human endoglin monoclonal antibodies (mAbs) which can be used as antiangiogenic agents for prophylaxis or therapy of human tumor angiogenesis and human angiogenesis-associated diseases having excessive vascularization. The mAbs do not cross react with murine endoglin. Also provides are methods for using the anti-human endoglin mAbs for prophylaxis or therapy of human tumor angiogenesis and for angiogenesis-associated diseases having excessive vascularization. | 02-13-2014 |
20140039571 | METHOD AND DEVICE TO RESTORE AND/OR IMPROVE NERVOUS SYSTEM FUNCTIONS BY MODIFYING SPECIFIC NERVOUS SYSTEM PATHWAYS - The present invention provides methods, devices, and systems for restoring or improving nervous system function of a subject. Provided is a method involving: (i) providing an operant conditioning protocol effective to produce targeted neural plasticity (TNP) in a primary targeted central nervous system (CNS) pathway of a subject; and (ii) administering the operant conditioning protocol to the subject to elicit TNP in the primary targeted CNS pathway and to elicit generalized neural plasticity (GNP) in one or more other CNS pathway. The elicitation of the GNP in the one or more other CNS pathway serves to restore or improve a nervous system function of the subject. Provided is a device comprising a nerve stimulation-electromyographic recording component and a controller for operating the nerve stimulation-electromyographic recording component in accordance with an operant conditioning protocol. | 02-06-2014 |
20130324503 | Method of identifying and treating a person having a predisposition to or afflicted with Parkinson disease - The present invention relates to methods of treatment for Parkinson Disease (PD) in a person by identifying gene variants which may indicate a more favorable response to specific medicaments, thereby allowing for personalized or individualized treatment. The present invention relates to a method of screening for a genetic predisposition to PD in a person. The present invention is also directed to a method of testing a person for the presence of particular gene variants, wherein the presence of a gene variant indicates a higher predisposition to PD, and the absence of a gene variant indicates a lower predisposition to PD, compared to a control sample. The present invention further relates to methods and kits for treating, or inhibiting the development of, PD in a person. The present invention is also directed to a method of identifying the heritage of an individual based on the genetic profile of the individual. | 12-05-2013 |
20130295540 | Method and System for Minimally-Invasive Surgery Training Using Tracking Data - A system and method for training a person in minimally-invasive surgery (“MIS”) utilizing a video of the MIS. The system comprises a processor, a display, and a first interaction device. The processor programmed to receive the video and to obtain tracking data. The tracking data may correspond to the motion of a tool controller. The tracking data may correspond to motion of a first surgical tool in the video. The processor programmed to calculate motion of the first interaction device corresponding to the tracking data, to display the video, and to cause the first interaction device to move according to the calculated motion. The method comprises receiving the video, obtaining the tracking data, calculating a motion of a first interaction device corresponding to the tracking data, displaying the video, and causing the first interaction device to move according to the calculated motion. | 11-07-2013 |
20130288214 | Method and System for Automatic Tool Position Determination for Minimally-Invasive Surgery Training - The present invention may be embodied as a method of minimally-invasive surgery (“MIS”) training using a video of an MIS comprising the steps of providing a processor, a display, and a first input device. The method comprises the step of processing the video using the processor to determine a location of the first surgical tool in each of the frames, determining whether the configuration of the first input device substantially corresponds to the location of the first surgical tool in each frame of the video while the video is displayed. The present invention may be embodied as a system for MIS training. The system comprises a processor, a communication device, and a first input device in communication with the processor. The processor is programmed perform any or all of the described disclosed methods. | 10-31-2013 |
20130237688 | MULTIMODALITY AGENTS FOR TUMOR IMAGING AND THERAPY - A compound that is a conjugate of an antagonist to an integrin expressed by a tumor cell and at least one of a tumor avid tetrapyrollic photosensitizer, a fluorescent dye, and a radioisotope labeled moiety wherein the radioisotope is | 09-12-2013 |
20130202526 | PAA NANOPARTICLES FOR PET IMAGING AND PDT TREATMENT - PAA nanoparticles containing at least one tetrapyrrolic photosensitizer and at least one PET imaging agent. | 08-08-2013 |
20130202525 | MULTIFUNCTIONAL NANOPLATFORMS FOR FLUORESCENCE IMAGING AND PHOTODYNAMIC THERAPY DEVELOPED BY POST-LOADING PHOTOSENSITIZER AND FLUOROPHORE TO POLYACRYLAMIDE NANOPARTICLES - A composition comprising PAA nanoparticles containing a post loaded tetrapyrollic photosensitizer and a postloaded imaging agent and methods for making and using same. | 08-08-2013 |
20130195758 | PAA NANOPLATFORMS CONTAINING FLUOROPHORES AND TARGETED MOIETIES COVALENTLY LINKED AND PHOTOSENSITIZER POST-LOADED - A PAA nanoparticle containing a covalently linked fluorescent dye and a post-loaded tetrapyrrolic photosensitizer. | 08-01-2013 |
20130150336 | Methods For Reducing Superoxide Anions in Eukaryotic Organisms - Provided are methods and compositions for reducing superoxide anions such that a prophylactic or therapeutic effect against conditions associated with excess oxidative stress achieved. The compositions and methods provide for reducing inflammation and for enhancing lifespan of eukaryotic organisms. A screen for identifying compounds that can be used in these methods is also provided. | 06-13-2013 |
20130072554 | Novel Method For Delivery and Use of Isothiocyanates For Prophylaxis and/or Therapy of Bladder Cancer - Provided is a composition that contains a mixture of broccoli seed and mustard seed. Before mixing the broccoli seed with the mustard seed, the broccoli seed is subjected to baking and a pressurized heat treatment. The broccoli seed is baked at a temperature of at least 200 degrees Fahrenheit for at least 60 minutes, and is subjected to a pressurized heat treatment of at least 200 degrees Fahrenheit at a pressure of at least 10 pounds/square inch for at least 5 minutes. Also provided is a method for therapy and/or prophylaxis of bladder cancer in an individual. The method entails administering orally to the individual a composition that contains an isothiocyanate (ITC) or a derivative thereof such that the administration inhibits the growth and/or recurrence of bladder cancer. Nutraceutical compositions are also provided. | 03-21-2013 |
20130011436 | Methods and Compositions Containing Fc Fusion Proteins for Enhancing Immune Responses - Provided are compositions and methods for inhibiting cell growth. The cells that are targeted by the compositions and methods of the invention express an antigen, a mimotope of the antigen, or a CXCR4 chemokine receptor. The method entails administering to an individual a polynucleotide encoding an immunoglobulin Fc and an antigen expressed by the cells or a mimotope of the antigen. The method also involves administering to the individual a composition which contains a polynucleotide encoding an immunoglobulin Fc and an antagonist peptide of a CXCR4 chemokine receptor expressed by the cells. Also provided are proteins encoded by the polynucleotides. | 01-10-2013 |
20120283269 | Method and Compositions for Suppression of Aging - The present invention provides a method of suppression and/or deceleration of mammalian cellular aging. The method involves contacting mammalian cells with a composition that contains a non-genotoxic inducer of p53 (NGIP). In certain embodiments, the NCIP is a Mdm-binding agent or Mdm-2 antagonist. The NGIP can be nutlin, nutlin-3A, a nutlin analog, or a combination thereof. The invention also provides a method for reducing cellular hypertrophy in an organism by administering a composition that contains an anti-hypertrophic compound, such as nutlin, nutlin-3A, a nutlin analog, rapamycin or a rapamycin analog and combinations thereof, to the organism. | 11-08-2012 |
20120264771 | Method for Treating Androgen Receptor Positive Cancers - Provided is a method of inhibiting growth of androgen receptor positive cancer cells. The method entails administering to an individual diagnosed with or suspected of having an androgen receptor positive cancer and administering to the individual a composition containing a compound that can inhibit the growth of the androgen receptor positive cancer. | 10-18-2012 |
20120097538 | METALLATION ENHANCEMENTS IN TUMOR-IMAGING AND PDT THERAPY - A compound in the form of a metallized tetrpyrollic photosensizer linked to a fluorescent dye where the photosensitizer (PS), is linked by a structure that does not have detrimental radiation emmitance or absorbing characteristics, to a fluorophore, usually a cyanine dye (CD). The photosensitizer in accordance the invention is a metallized analog of porphyrins, chlorins, purpurinimides, bacterio pupurinimides, phthalocyanines, expanded porphyrins, benzoporphyrin derivatives and purpurins. The fluorophore is usually a cyanine dye with varaible substituents. And, A method for determining effectiveness of PDT by comparing proportion of STAT-3 monomer with crosslinked STAT-3 dimer after PDT where the relative proportion of STAT-3 monomer to crosslinked STAT-3 directly correlates to efficacy of the PDT. | 04-26-2012 |
20110312016 | Method for Evaluating Immunosuppression - Provided is a method for determining immunosuppression in an individual. The method entails obtaining a sample of blood from an individual, contacting cells in the blood sample with an activating agent to obtain activated cells, measuring the amount of nuclear NFkB in the activated cells, and comparing the amount of nuclear NFkB in the activated cells to a control. An amount of nuclear NFkB that is higher than the control is considered to be indicative of insufficient immunosuppression in the individual. An amount of nuclear NFkB that is lower than the control is considered to he indicative of excessive immunosuppression in the individual. An amount of nuclear NFkB that is the same as the control is considered to be indicative of an appropriate amount of immunosuppression in the individual. | 12-22-2011 |
20110288234 | SILICA NANOPARTICLES POSTLOADED WITH PHOTOSENSITIZERS FOR DRUG DELIVERY IN PHOTODYNAMIC THERAPY - A nanoparticle including a polysiloxane base having an exterior surface and having a photosensitizer at least partly exposed at its exterior surface, said photosensitizer being secured to the exterior surface by loading the photosensitizer onto the surface after formation of the polysiloxane base of the nanoparticle. The nanoparticle may have tumor targeting moieties and may be post loaded with cyanine dye. The nanoparticle preferably includes post loaded moieties providing at least two of tumor specificity, photodynamic properties and imaging capabilities and the photosensitizer is tagged with a radioisotope. A method for preparation of the nanoparticle is also provided. | 11-24-2011 |
20110268755 | Survivin Peptides For Autoimmune Therapies - Compositions and methods for stimulating an immune response against cells that express survivin are provided. The method is suitable for prophylaxis and/or therapy of autoimmune disorders. The method involves administering to an individual a composition that contains a survivin peptide mimic that has a cysteine to methionine alteration at amino acid position 57 of wild type survivin. Fragments of the peptides can also be used. | 11-03-2011 |
20110264027 | B RING REDUCED-D RING OXIDIZED TETRAPYROLLIC PHOTOSENSITIZERS FOR PHOTODYNAMIC THERAPY AND TUMOR IMAGING - Tetrapyrollic photosensitizers and imaging agent compounds having A, B, C, and D rings and having a reduced B ring and an oxidized D ring. The compounds preferably have a purity of at least 95 percent and preferably have a fused system connected at an unsaturated carbon atom of the C ring nearest the D ring and at the unsaturated carbon atom between the C and D rings. The invention also includes a method of making the compounds at over 95 percent yield by starting with a B and D ring oxidized tetrapyrollic compound and dissolving it in a halogenated hydrocarbon solvent and treating it with sufficient nitroalkane solution of FeCl | 10-27-2011 |
20110223102 | MULTIMODALITY AGENTS FOR TUMOR IMAGING AND THERAPY - A compound that is a conjugate of an antagonist to an integrin expressed by a tumor cell and at least one of a tumor avid tetrapyrollic photosensitizer, a fluorescent dye, and a radioisotope labeled moiety wherein the radioisotope is | 09-15-2011 |
20110212986 | ANTI-FLAVIVIRUS THERAPEUTIC - The present invention relates to anti-flavivirus compounds, including lycorine and derivatives thereof, and their use in treating a subject infected by a flavivirus. The present invention also relates to the use of the anti-flavivirus compounds for the prophylaxis of flavivirus infection. The present invention further relates to a method of suppressing viral RNA synthesis of a flavivirus. Also described is a method of preparing an anti-flavivirus compound for use in the treatment or prophylaxis of flavivirus infection. | 09-01-2011 |
20110091390 | WATER SOLUBLE TETRAPYROLLIC PHOTOSENSITIZERS FOR PHOTODYNAMIC THERAPY - A tetrapyrollic photosensitizer compound having at least one pendant —CH | 04-21-2011 |
20110091373 | PAA NANOPARTICLES FOR ENHANCEMENT OF TUMOR IMAGING - A composition comprising PAA nanoparticles containing a post loaded tetrapyrollic photosensitizer and an imaging agent and methods for making and using same. | 04-21-2011 |
20100221763 | Specific Acceptors for Transferases to Saccharides and Method for Obtaining and Using Same - A method for determining substrates specific for a transferase enzyme selected from the group consisting of glycosyltransferases and sulfotransferases. The method includes the steps of:
| 09-02-2010 |
20100184970 | Porphyrin-based compounds for tumor imaging and photodynamic therapy - This invention describes a first report on the synthesis of certain | 07-22-2010 |
20100144820 | THERAPEUTIC HPPH DOSAGE FOR PDT - A method for treating cancer and other hyperproliferative tissues in humans that can be exposed to light comprising injection of HPPH at the equivalent to a dose of 0.05 to 0.11 mg/kg of body weight 24 hours post injection and exposing the tumor or other hyperproliferative tissue to 665±10 nm of light at 50 to 200 Joules/cm | 06-10-2010 |
20100137396 | TREATMENT OF ESOPHAGEAL HIGH GRADE DYSPLASIA USING PHOTODYNAMIC THERAPY - A method for treatment of esophageal high grade dysplasia comprising the steps of: injecting HPPH in a physiologically compatible medium into a patient having high grade dysplasia tissue to provide a dose level of 3 through 5 mg/m | 06-03-2010 |
20100130909 | TREATMENT OF BARRETT'S ESOPHAGUS USING PHOTODYNAMIC THERAPY - A method for treatment of Barrett's esophagus comprising the steps of: injecting HPPH in a physiologically compatible medium into a patient having Barrett's esophagus tissue to provide a dose level of 3 through 5 mg/m | 05-27-2010 |
20100068729 | METHOD AND KITS FOR THE DIAGNOSIS OF DIABETES - Provided are methods for the detection and diagnosis of a predisposition for developing diabetes. The methods are based on the discovery that abnormal levels of the selected analyte in biological samples, typically blood samples, of patients who are at risk are supportive of a diagnosis of a predisposition for developing diabetes. At least one new biomarker for a predisposition for diabetes is thus disclosed, IGF-1. Other important biomarkers for diabetes are described, including but not limited to ZAG, clusterin, corticosteroid-binding globulin, lumican, and serotransferrin. Kits containing reagents to assist in the analysis of biological samples are also described. | 03-18-2010 |
20100056983 | Treatment of cancer using photodynamic therapy - A method for treatment of cancerous tissue in the upper respiratory system including the steps of: injecting HPPH in a physiologically compatible medium into a patient having the cancerous tissue at a level of 3 through 5 mg/m | 03-04-2010 |
20090162289 | Water soluble tetrapyrollic photosensitizers for photodynamic therapy - A tetrapyrollic photosensitizer compound having at least one pendant —CH | 06-25-2009 |
20090117548 | ANALYSIS OF HIV-1 CORECEPTOR USE IN THE CLINICAL CARE OF HIV-1 INFECTED PATIENTS - A change in viral tropism occurs in many HIV positive individuals over time and can be indicated by a change in coreceptor usage from CCR5 to CXCR4. The change in coreceptor usage to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the predominant populations of virus can be shifted back to CCR5-mediated entry after the CXCR4-specific strains have emerged. The present invention relates to a diagnostic method to monitor coreceptor use in the treatment of human immunodeficiency virus (HIV) infection. The present invention further relates to a diagnostic method applied to HIV-positive individuals undergoing HAART to monitor the suppression of CXCR4 specific strains. The diagnostic methods can be used to assist in selecting antiretroviral therapy and to improve predictions of disease prognosis over time. | 05-07-2009 |
20090081674 | Methods for Analysis of PDEF and Survivin as Interconnected Cancer Biomarkers and Targets for Personalized Medicine - Provided are methods for determining whether an individual is a candidate to receive treatment with a DNA methylation inhibitor. The method can be performed a biological sample of cancerous tissue of the individual. Determining that PDEF expression is absent or low and survivin expression is present identifies the individual as a candidate to receive a treatment with a DNA methylation inhibitor. The method also includes communicating the result of identifying an individual as a candidate for receiving a DNA methylation inhibitor to a health care provider | 03-26-2009 |
20090043090 | ADDUCT OF FLUORESCENT DYE AND TUMOR AVID TETRAPYRROLE - A compound having preferential localization in tumor tissue relative to normal tissue, a preferential electromagnetic absorption at a wavelength between about 660 and 900 nm, and a fluorescence at a wavelength shifted from the preferential absorption by at least +30 nm and preferably at least +50 nm. The compound further preferably destroys tumor tissue in which it is absorbed when exposed to light at its preferential absorption wavelength. In a preferred embodiment of the invention, the compound is a conjugate of a tumor avid tetrapyrrole compound with a fluorescent dye, and more preferably the fluorescent dye is an indocyanine dye such as indocyanine green. The tumor avid tetrapyrrole compound is preferably a porphyrin derivative selected from the group consisting of chlorins, bacteriochlorins, purpurins and derivatives thereof. | 02-12-2009 |
20090041732 | Survivin Peptides As Cancer Vaccines - Provided are compositions and methods for treating survivin expressing cancers. The compositions contain peptide survivin peptide mimics with improved MHC-I binding characteristics. The method involves administering a survivin peptide mimic with improved MHC-I binding characteristics to an individual to effect inhibition of the growth of survivin expressing cancer cells in the individual. | 02-12-2009 |
20090035749 | ANALYSIS OF HIV-1 CORECEPTOR USE IN THE CLINICAL CARE OF HIV-1 INFECTED PATIENTS - A change in viral tropism occurs in many HIV positive individuals over time and can be indicated by a shift in coreceptor use from CCR5 to CXCR4. The shift in coreceptor use to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the predominant populations of virus can be shifted back to CCR5-mediated entry after the CXCR4-specific strains have emerged. The present invention relates to a diagnostic method to monitor coreceptor use in the treatment of human immunodeficiency virus (HIV) infection. The present invention further relates to a diagnostic method applied to HIV-positive individuals undergoing HAART to monitor the suppression of CXCR4 specific strains. The diagnostic methods can be used to assist in selecting antiretroviral therapy and to improve predictions of disease prognosis over time. | 02-05-2009 |
20080261253 | Methods and kits for the diagnosis of galactosemia - Provided are methods for the detection and diagnosis of galactosemia. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of galactosemia. At least two new biomarkers for galactosemia are thus disclosed, Eotaxin and MCP-1. Altogether the concentrations these markers, individually, or in combinations with any of Alpha-2 Macroglobulin, Apolipoprotein H, Cancer Antigen 125, Leptin, TNF RII, Alpha-Fetoprotein, IgM, MIP-1 alpha, Ferritin, and IgE provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering from galactosemia. Kits containing reagents to assist in the analysis of fluid samples are also described. | 10-23-2008 |
20080255766 | Methods and kits for the diagnosis of sickle cell - Provided are methods for the detection and diagnosis of sickle cell. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of sickle cell. At least two new biomarkers for sickle cell are thus disclosed, Eotaxin and Monocyte Chemotactic Protein-1. Altogether the concentrations of eleven analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering from sickle cell. Other important biomarkers for sickle cell are described, including but not limited to IL-12p40, SHBG, MMP-9, Adiponectin, Haptoglobin, FGF basic, IgM, Growth Hormone, Factor VII. Kits containing reagents to assist in the analysis of fluid samples are also described. | 10-16-2008 |